Skip to content

Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure

France approves PrEP

Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows

How do we treat the world? Experts discuss moving to universal HIV treatment

Retreat of international donors and neglect of national governments threatens harm reduction services

Dr S. Subramaniam, Malaysian Minister of Health, at IHRC 2015. Photograph © 2015 Ahmad Yusni/Harm Reduction International.

Second UK cost-effectiveness study finds that large PrEP programmes may need drug price cut to be affordable

Where next in PrEP and microbicides? Europeans discuss research pipeline

Provision of PrEP in the UK will be cost-effective for gay men at high risk of HIV, model finds

High lifetime costs of treating HIV show importance of investing in prevention